

EAST Search History

| Ref # | Hits | Search Query | DBs | Default Operator | Plurals | Time Stamp |
|-------|--------|---|---|------------------|---------|------------------|
| L1 | 1431 | 564/336.ccls. or 562/590.ccls. or 514/554.ccls. | US-PGPUB; USPAT; EPO; JPO; DERWENT | OR | ON | 2007/06/29 10:05 |
| L2 | 73813 | microcrystalline | US-PGPUB; USPAT; EPO; JPO; DERWENT | OR | ON | 2007/06/29 10:05 |
| L3 | 2459 | \$venlafaxine | US-PGPUB; USPAT; EPO; JPO; DERWENT | OR | ON | 2007/06/29 10:05 |
| L4 | 98265 | fumaric | US-PGPUB; USPAT; EPO; JPO; DERWENT | OR | ON | 2007/06/29 10:05 |
| L5 | 216614 | succin\$ | US-PGPUB; USPAT; EPO; JPO; DERWENT | OR | ON | 2007/06/29 10:05 |
| L6 | 11 | fumaric near3 toxicity | US-PGPUB; USPAT; EPO; JPO; DERWENT | OR | ON | 2007/06/29 10:05 |
| L7 | 11 | \$venlafaxine and 514/554.ccls. | US-PGPUB; USPAT; EPO; JPO; DERWENT | OR | ON | 2007/06/29 10:05 |
| L8 | 320 | 564/336.ccls. | US-PGPUB; USPAT; EPO; JPO; DERWENT | OR | ON | 2007/06/29 10:05 |
| L9 | 1617 | \$venlafaxine and succin\$ | US-PGPUB; USPAT; EPO; JPO; DERWENT | OR | ON | 2007/06/29 10:05 |
| L10 | 612 | 562/590.ccls. | US-PGPUB; USPAT; EPO; JPO; DERWENT | OR | ON | 2007/06/29 10:05 |
| L11 | 65585 | succinate | US-PGPUB; USPAT; EPO; JPO; DERWENT | OR | ON | 2007/06/29 10:05 |

EAST Search History

| | | | | | | |
|-----|--------|---|---|----|-----|------------------|
| L12 | 512 | 514/554.ccls. | US-PGPUB; USPAT; EPO; JPO; DERWENT | OR | ON | 2007/06/29 10:05 |
| L13 | 30 | "4535186".URPN. | USPAT | OR | ON | 2007/06/29 10:05 |
| L14 | 1127 | \$venlafaxine and succinate | US-PGPUB; USPAT; EPO; JPO; DERWENT | OR | ON | 2007/06/29 10:05 |
| L15 | 132 | succin\$ and 562/590.ccls. | US-PGPUB; USPAT; EPO; JPO; DERWENT | OR | ON | 2007/06/29 10:05 |
| L16 | 1362 | (dosage adj form) and (\$venlafaxine and succin\$) | US-PGPUB; USPAT; EPO; JPO; DERWENT | OR | ON | 2007/06/29 10:05 |
| L17 | 190559 | toxicity | US-PGPUB; USPAT; EPO; JPO; DERWENT | OR | ON | 2007/06/29 10:05 |
| L18 | 1694 | (dosage adj form) and \$venlafaxine | US-PGPUB; USPAT; EPO; JPO; DERWENT | OR | ON | 2007/06/29 10:05 |
| L19 | 108249 | dosage adj form | US-PGPUB; USPAT; EPO; JPO; DERWENT | OR | ON | 2007/06/29 10:05 |
| L20 | 23 | toxicity | US-PGPUB; USPAT; EPO; JPO; DERWENT | OR | ON | 2007/06/29 10:05 |
| L21 | 175 | \$venlafaxine same succinate | US-PGPUB; USPAT; EPO; JPO; DERWENT | OR | ON | 2007/06/29 10:05 |
| L22 | 23 | toxicity | US-PGPUB; USPAT; EPO; JPO; DERWENT | OR | ON | 2007/06/29 10:05 |
| L23 | 28534 | (dosage adj form) and microcrystalline | US-PGPUB; USPAT; EPO; JPO; DERWENT | OR | ON | 2007/06/29 10:05 |
| L24 | 1 | "4269788".PN. | USPAT | OR | OFF | 2007/06/29 10:05 |

EAST Search History

| | | | | | | |
|-----|--------|--|---|----|-----|------------------|
| L25 | 1 | "0032555".pn. | US-PGPUB; USPAT; EPO; JPO; DERWENT | OR | ON | 2007/06/29 10:05 |
| L26 | 2 | "4535186".pn. | US-PGPUB; USPAT; EPO; JPO; DERWENT | OR | ON | 2007/06/29 10:05 |
| L27 | 19 | (\$venlafaxine and (564/336.ccls. or 562/590.ccls. or 514/554.ccls.)) and succin\$ | US-PGPUB; USPAT; EPO; JPO; DERWENT | OR | ON | 2007/06/29 10:05 |
| L28 | 10 | 562/590.ccls. and 514/554.ccls. | US-PGPUB; USPAT; EPO; JPO; DERWENT | OR | ON | 2007/06/29 10:05 |
| L29 | 34 | \$venlafaxine near3 succinate | US-PGPUB; USPAT; EPO; JPO; DERWENT | OR | ON | 2007/06/29 10:05 |
| L30 | 15 | 564/336.ccls. and \$venlafaxine | US-PGPUB; USPAT; EPO; JPO; DERWENT | OR | ON | 2007/06/29 10:05 |
| L31 | 4 | \$venlafaxine and 562/590.ccls. | US-PGPUB; USPAT; EPO; JPO; DERWENT | OR | ON | 2007/06/29 10:05 |
| L32 | 27 | \$venlafaxine and (564/336.ccls. or 562/590.ccls. or 514/554.ccls.) | US-PGPUB; USPAT; EPO; JPO; DERWENT | OR | ON | 2007/06/29 10:05 |
| L33 | 2 | "6375982".pn. | US-PGPUB; USPAT; EPO; JPO; DERWENT | OR | ON | 2007/06/29 10:05 |
| L34 | 213980 | cellulose | USPAT | OR | ON | 2007/06/29 10:05 |
| L35 | 23 | desmethylenlafaxine | USPAT | OR | ON | 2007/06/29 10:05 |
| L36 | 20 | L35 and L34 | USPAT | OR | ON | 2007/06/29 10:05 |
| L37 | 2 | "6395300".pn. | US-PGPUB; USPAT; EPO; JPO; DERWENT | OR | ON | 2007/06/29 10:05 |
| L38 | 2 | ("4535186").PN. | US-PGPUB; USPAT; EPO; JPO; DERWENT | OR | OFF | 2007/06/29 10:05 |

EAST Search History

| | | | | | | |
|-----|---------|--------------------------------------|---|----|-----|------------------|
| L39 | 0 | ("microcrystallineadjcellulose").PN. | US-PGPUB; USPAT; EPO; JPO; DERWENT | OR | OFF | 2007/06/29 10:05 |
| L40 | 42905 | microcrystalline adj cellulose | US-PGPUB; USPAT; EPO; JPO; DERWENT | OR | ON | 2007/06/29 10:05 |
| L41 | 2 | ("6274171").PN. | US-PGPUB; USPAT; EPO; JPO; DERWENT | OR | OFF | 2007/06/29 10:05 |
| L42 | 12 | L35 and L40 | US-PGPUB; USPAT; EPO; JPO; DERWENT | OR | ON | 2007/06/29 10:05 |
| L43 | 109 | L3 same L40 | US-PGPUB; USPAT; EPO; JPO; DERWENT | OR | ON | 2007/06/29 10:05 |
| L44 | 1 | "4535186".PN. | USPAT | OR | ON | 2007/06/29 10:05 |
| L45 | 3 | 564/336.ccls. and 562/590.ccls. | US-PGPUB; USPAT; EPO; JPO; DERWENT | OR | ON | 2007/06/29 10:05 |
| L46 | 2210140 | polymer | US-PGPUB; USPAT; EPO; JPO; DERWENT | OR | ON | 2007/06/29 10:05 |
| L47 | 3716 | L40 same L46 | US-PGPUB; USPAT; EPO; JPO; DERWENT | OR | ON | 2007/06/29 10:05 |
| L48 | 617 | L40 near5 L46 | US-PGPUB; USPAT; EPO; JPO; DERWENT | OR | ON | 2007/06/29 10:07 |
| L49 | 893 | L3 and L40 | US-PGPUB; USPAT; EPO; JPO; DERWENT | OR | ON | 2007/06/29 10:05 |
| L50 | 2 | ("20040106576").PN. | US-PGPUB; USPAT; EPO; JPO; DERWENT | OR | OFF | 2007/06/29 10:05 |
| L51 | 78 | L3 near10 L40 | US-PGPUB; USPAT; EPO; JPO; DERWENT | OR | ON | 2007/06/29 10:05 |
| | | | USPAT; EPO; JPO; DERWENT | | | |

EAST Search History

| | | | | | | |
|-----|------|--|---|----|-----|------------------|
| L52 | 73 | L3 near5 L40 | US-PGPUB; USPAT; EPO; JPO; DERWENT | OR | ON | 2007/06/29 10:05 |
| L53 | 1104 | L40 near10 L46 | US-PGPUB; USPAT; EPO; JPO; DERWENT | OR | ON | 2007/06/29 10:05 |
| L54 | 30 | US-5788986-\$.DID. or US-5733566-\$. DID. or US-5674533-\$.DID. or US-5639476-\$.DID. or US-5591767-\$. DID. or US-5354556-\$.DID. or US-5120548-\$.DID. or US-5073543-\$. DID. or US-5059595-\$.DID. or US-4761501-\$.DID. or US-4008719-\$. DID. or US-3916899-\$.DID. or US-3845770-\$.DID. or US-3598123-\$. DID. or US-3536809-\$.DID. | US-PGPUB; USPAT; EPO; JPO; DERWENT | OR | ON | 2007/06/29 10:18 |
| L55 | 1 | I3 and I54 | US-PGPUB; USPAT; EPO; JPO; DERWENT | OR | ON | 2007/06/29 10:09 |
| L56 | 2 | ("20050175698").PN. | US-PGPUB; USPAT; EPO; JPO; DERWENT | OR | OFF | 2007/06/29 10:19 |
| L57 | 2 | ("20040181093").PN. | US-PGPUB; USPAT; EPO; JPO; DERWENT | OR | OFF | 2007/06/29 10:20 |
| L58 | 2 | ("6689912").PN. | US-PGPUB; USPAT; EPO; JPO; DERWENT | OR | OFF | 2007/06/29 10:20 |
| L59 | 2 | ("20030236309").PN. | US-PGPUB; USPAT; EPO; JPO; DERWENT | OR | OFF | 2007/06/29 10:25 |
| L60 | 2 | ("20030149112").PN. | US-PGPUB; USPAT; EPO; JPO; DERWENT | OR | OFF | 2007/06/29 10:25 |

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1623PAZ

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page for STN Seminar Schedule - N. America
NEWS 2 MAR 15 WPIDS/WPIX enhanced with new FRAGHITSTR display format
NEWS 3 MAR 16 CASREACT coverage extended
NEWS 4 MAR 20 MARPAT now updated daily
NEWS 5 MAR 22 LWPI reloaded
NEWS 6 MAR 30 RDISCLOSURE reloaded with enhancements
NEWS 7 APR 02 JICST-EPLUS removed from database clusters and STN
NEWS 8 APR 30 GENBANK reloaded and enhanced with Genome Project ID field
NEWS 9 APR 30 CHEMCATS enhanced with 1.2 million new records
NEWS 10 APR 30 CA/CAPplus enhanced with 1870-1889 U.S. patent records
NEWS 11 APR 30 INPADOC replaced by INPADOCDB on STN
NEWS 12 MAY 01 New CAS web site launched
NEWS 13 MAY 08 CA/CAPplus Indian patent publication number format defined
NEWS 14 MAY 14 RDISCLOSURE on STN Easy enhanced with new search and display fields
NEWS 15 MAY 21 BIOSIS reloaded and enhanced with archival data
NEWS 16 MAY 21 TOXCENTER enhanced with BIOSIS reload
NEWS 17 MAY 21 CA/CAPplus enhanced with additional kind codes for German patents
NEWS 18 MAY 22 CA/CAPplus enhanced with IPC reclassification in Japanese patents
NEWS 19 JUN 27 CA/CAPplus enhanced with pre-1967 CAS Registry Numbers
NEWS EXPRESS NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 09:36:48 ON 29 JUN 2007

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 09:37:04 ON 29 JUN 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 28 JUN 2007 HIGHEST RN 940062-32-8
DICTIONARY FILE UPDATES: 28 JUN 2007 HIGHEST RN 940062-32-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=> e o-desmethylvenlafaxine/cn

| | | |
|-----|---|--|
| E1 | 1 | O-DESMETHYLTHEBACONE/CN |
| E2 | 1 | O-DESMETHYLTRAMADOL-HYDROCODONE MIXT./CN |
| E3 | 1 | --> O-DESMETHYLVENLAFAXINE/CN |
| E4 | 1 | O-DESMETHYLVENLAFAXINE SULFATE/CN |
| E5 | 1 | O-DESULFOHEPARIN/CN |
| E6 | 1 | O-DETA/CN |
| E7 | 1 | O-DEUTERIOBENZOIC ACID/CN |
| E8 | 1 | O-DEUTERIOBENZOPHENONE/CN |
| E9 | 1 | O-DEUTERIOTOLUENE/CN |
| E10 | 1 | O-DEUTEROANILINE/CN |
| E11 | 1 | O-DEUTEROBENZOIC ACID/CN |
| E12 | 1 | O-DEUTEROBENZONITRILE/CN |

=> e3

L1 1 O-DESMETHYLVENLAFAXINE/CN

=> d l1

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2007 ACS on STN
RN 93413-62-8 REGISTRY
ED Entered STN: 18 Dec 1984
CN Phenol, 4-[2-(dimethylamino)-1-(1-hydroxycyclohexyl)ethyl]- (CA INDEX
NAME)

OTHER NAMES:

CN 4-[2-(Dimethylamino)-1-(1-hydroxycyclohexyl)ethyl]phenol

CN Desvenlafaxine

CN DVS 233

CN O-Desmethylvenlafaxine


DR 130198-07-1

MF C16 H25 N O2

CI COM

LC STN Files: ADISINSIGHT, ADISNEWS, ANABSTR, BEILSTEIN*, BIOSIS, CA,
CAPLUS, CASREACT, CHEMCATS, CIN, HSDB*, IMSDRUGNEWS, IMSPATENTS,
IMSRESEARCH, MEDLINE, PHAR, PROMT, PROUSDDR, SYNTHLINE, TOXCENTER, USAN,
USPAT2, USPATFULL

(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

129 REFERENCES IN FILE CA (1907 TO DATE)
 3 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 130 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> file caplus
 COST IN U.S. DOLLARS

| SINCE FILE | TOTAL |
|------------|---------|
| ENTRY | SESSION |
| 9.15 | 9.36 |

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 09:40:20 ON 29 JUN 2007
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 29 Jun 2007 VOL 147 ISS 2
 FILE LAST UPDATED: 28 Jun 2007 (20070628/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> succinate
 51613 SUCCINATE
 1235 SUCCINATES
 L2 52134 SUCCINATE
 (SUCCINATE OR SUCCINATES)

=> succinnic
 L3 12 SUCCINNIC

=> succinic
 L4 63415 SUCCINIC

=> 12 or 14
 L5 102886 L2 OR L4

=> 11
 L6 130 L1

=> 15 and 16

L7

6 L5 AND L6

=> d 17 1-6 ti fbib abs

L7 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN
TI Combinations of eszopiclone and O-desmethylvenlafaxine for treatment of
menopause and mood, anxiety, and cognitive disorders
AN 2007:33965 CAPLUS
DN 146:128638
TI Combinations of eszopiclone and O-desmethylvenlafaxine for treatment of
menopause and mood, anxiety, and cognitive disorders
IN Caron, Judy; Wessel, Thomas; Lalji, Karim; Varney, Mark A.
PA Sepracor Inc., USA
SO PCT Int. Appl., 42pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|---|------|----------|-----------------|----------|
| PI | WO 2007005961 | A2 | 20070111 | WO 2006-US26185 | 20060705 |
| | WO 2007005961 | A3 | 20070222 | | |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW | | | | |
| | RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |

US 2005-697012P P 20050706

AB One aspect of the present invention relates to pharmaceutical compns.
containing 2 or more active agents that when taken together can be used to
treat, e.g., menopause, mood disorders, anxiety disorders, or cognitive
disorders. The first component of the pharmaceutical composition is a sedative
eszopiclone. The second component of the pharmaceutical composition is
O-desmethylvenlafaxine. The present invention also relates to a method of
treating menopause, perimenopause, mood disorders, anxiety disorders, and
cognitive disorders. Thus, a capsule contained eszopiclone 3.0,
O-Desmethylvenlafaxine succinate salt monohydrate 303.4, Avicel
PH102 198.9, dibasic calcium phosphate 90.0, Croscarmellose sodium 6.0,
colloidal silica 0.6, and Mg stearate 1.5 mg/unit.

L7 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN
TI O-Desmethylvenlafaxine and bazedoxifene combination product and uses
thereof
AN 2006:1041211 CAPLUS
DN 145:383564
TI O-Desmethylvenlafaxine and bazedoxifene combination product and uses
thereof
IN Shah, Syed; Fawzi, Mahdi; Diorio, Christopher
PA Wyeth, John, and Brother Ltd., USA
SO PCT Int. Appl., 37pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|--|------|----------|-----------------|----------|
| PI | WO 2006104791 | A1 | 20061005 | WO 2006-US10335 | 20060322 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, | | | | |

CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

US 2006223791 A1 20061005 US 2005-666902P P 20050331
 US 2006-386420 20060322
 US 2005-666902P P 20050331

AB A combination product containing at least two active compds., O-desmethylvenlafaxine (ODV) or a pharmaceutically acceptable salt thereof and bazedoxifene (BZA) or a pharmaceutically acceptable salt thereof is described. Also described are methods of making and using this combination product to treat a variety of conditions associated with low circulating estrogen levels or low estrogen receptor activity. Thus, bi-layer tablets were prepared by compression of 150 mg of desvenlafaxine succinate (DVS) granulation and 40 mg of bazedoxifene acetate granulation. Both BZA and DVS were stable in 25°/60% relative humidity and 40°/75% relative humidity for 3 mo. Almost complete releases from bilayer tablets in 24 h were achieved for both BZA and DVS.

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN
 TI Desvenlafaxine succinate: antidepressant treatment of postmenopausal syndrome 5-HT and norepinephrine reuptake inhibitor
 AN 2006:708630 CAPLUS
 DN 146:19037
 TI Desvenlafaxine succinate: antidepressant treatment of postmenopausal syndrome 5-HT and norepinephrine reuptake inhibitor
 AU Sorbera, L. A.; Bolos, J.; Serradell, N.
 CS Prous Science, Barcelona, 08080, Spain
 SO Drugs of the Future (2006), 31(4), 304-309
 CODEN: DRFUD4; ISSN: 0377-8282

PB Prous Science
 DT Journal; General Review
 LA English

AB A review. There are three major classes of drugs available for the pharmacotherapy of depression: tricyclic antidepressants, monoamine oxidase (MAO) inhibitors and selective serotonin reuptake inhibitors (SSRIs). Venlafaxine, a tricyclic compound which was launched in 1994, was the first serotonin and norepinephrine reuptake inhibitor (SNRI) and exhibited particular efficacy as a first-line treatment for major depression, being devoid of the anti-cholinergic, sedative and cardiovascular adverse events common to many antidepressants. In an effort to further improve the efficacy and safety profile of this agent, several oxidative metabolites of venlafaxine were identified. Of these metabolites, O-desmethylvenlafaxine (desvenlafaxine, DVS-233, WY-45233) displayed the greatest preclin. antidepressant activity and tolerability and was chosen for further development. Preclin. studies also indicated that desvenlafaxine may be effective in relieving vasomotor symptoms associated with menopause (i.e., hot flashes and night sweats). The succinate salt is preregistered for the treatment of major depression and continues to undergo testing for the relief of vasomotor symptoms associated with menopause.

RE.CNT 53 THERE ARE 53 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN
 TI Multiparticulate O-desmethylvenlafaxine salts and uses thereof

AN 2005:735104 CAPLUS
 DN 143:199895
 TI Multiparticulate O-desmethylvenlafaxine salts and uses thereof
 IN Diorio, Christopher Richard; Shah, Syed M.; Fawzi, Mahdi B.
 PA Wyeth, John, and Brother Ltd., USA
 SO U.S. Pat. Appl. Publ., 7 pp.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----------------|---|------|----------|------------------|------------|
| PI | US 2005175698 | A1 | 20050811 | US 2005-42436 | 20050125 |
| | | | | US 2004-542384P | P 20040206 |
| | AU 2005212166 | A1 | 20050825 | AU 2005-212166 | 20050125 |
| | | | | US 2004-542384P | P 20040206 |
| | | | | WO 2005-US2215 | W 20050125 |
| | CA 2554559 | A1 | 20050825 | CA 2005-2554559 | 20050125 |
| | | | | US 2004-542384P | P 20040206 |
| | | | | WO 2005-US2215 | W 20050125 |
| | WO 2005077340 | A1 | 20050825 | WO 2005-US2215 | 20050125 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| | RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | | | | US 2004-542384P | P 20040206 |
| EP 1711167 | | A1 | 20061018 | EP 2005-711931 | 20050125 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU | | | | |
| | | | | US 2004-542384P | P 20040206 |
| | | | | WO 2005-US2215 | W 20050125 |
| CN 1917860 | | A | 20070221 | CN 2005-80004251 | 20050125 |
| | | | | US 2004-542384P | P 20040206 |
| | | | | WO 2005-US2215 | W 20050125 |
| IN 2006KN02078 | | A | 20070518 | IN 2006-KN2078 | 20060724 |
| | | | | US 2004-542384P | P 20040206 |
| | | | | WO 2005-US2215 | W 20050125 |
| NO 2006003963 | | A | 20060905 | NO 2006-3963 | 20060905 |
| | | | | US 2004-542384P | P 20040206 |
| | | | | WO 2005-US2215 | W 20050125 |

AB A multiparticulate O-desmethylvenlafaxine (ODV) succinate or formate is described. Methods of treating depression and reducing the gastrointestinal side-effects of ODV are also described.

L7 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN
 TI Therapeutic compositions including resin-loaded bioavailability enhancers
 AN 2004:1035019 CAPLUS
 DN 142:11574
 TI Therapeutic compositions including resin-loaded bioavailability enhancers
 IN Hughes, Lyn
 PA Rohm and Haas Company, USA
 SO Eur. Pat. Appl., 10 pp.
 CODEN: EPXXDW
 DT Patent
 LA English
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|--|------------|------|------|-----------------|------|
|--|------------|------|------|-----------------|------|

| | | | | | |
|----|---|----|----------|------------------|------------|
| PI | EP 1481690 | A1 | 20041201 | EP 2004-252933 | 20040518 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR | | | | |
| | | | | US 2003-474663P | P 20030530 |
| | JP 2004359665 | A | 20041224 | JP 2004-29032 | 20040205 |
| | | | | US 2003-474663P | P 20030530 |
| | CN 1572326 | A | 20050202 | CN 2004-10047596 | 20040526 |
| | | | | US 2003-474663P | P 20030530 |
| | US 2004241135 | A1 | 20041202 | US 2004-854906 | 20040527 |
| | | | | US 2003-474663P | P 20030530 |

AB The present invention relates to a resin comprising a bio-enhancer and an optional therapeutically active ingredient or precursor thereof loaded thereon. The bio-enhancer is ionizable or non-ionizable, and the resin may be a cation exchange resin or an anion exchange resin. For example, resin loaded with both active ingredient and bioenhancers was produced by mixing O-desmethylvenlafaxine with strongly basic anion exchange resin ethanol solns., followed by adding succinic acid and then filtered and dried to obtain the resinate containing O-desmethylvenlafaxine succinate.

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L7 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN
TI Novel succinate salt of O-desmethylvenlafaxine
AN 2002:637634 CAPLUS
DN 137:190735
TI Novel succinate salt of O-desmethylvenlafaxine
IN Hadfield, Anthony Francis; Shah, Syed Muzafar; Winkley, Michael William; Sutherland, Karen Wiggins; Provost, James Andrew; Park, Aeri; Shipplett, Rex Alwyn; Russell, Brenton William; Weber, Beat Theodor
PA Wyeth, John, and Brother Ltd., USA
SO PCT Int. Appl., 76 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|---|------|----------|-----------------|------------|
| PI | WO 2002064543 | A2 | 20020822 | WO 2002-US4103 | 20020211 |
| | WO 2002064543 | A3 | 20021212 | | |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW | | | | |
| | RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | | | | US 2001-268214P | P 20010212 |
| | | | | US 2001-297963P | P 20010613 |
| | CA 2436668 | A1 | 20020822 | CA 2002-2436668 | 20020211 |
| | | | | US 2001-268214P | P 20010212 |
| | | | | US 2001-297963P | P 20010613 |
| | | | | WO 2002-US4103 | W 20020211 |
| | AU 2002250058 | A1 | 20020828 | AU 2002-250058 | 20020211 |
| | | | | US 2001-268214P | P 20010212 |
| | | | | US 2001-297963P | P 20010613 |
| | | | | WO 2002-US4103 | W 20020211 |
| | US 2003045583 | A1 | 20030306 | US 2002-73743 | 20020211 |
| | US 6673838 | B2 | 20040106 | | |
| | | | | US 2001-268214P | P 20010212 |
| | | | | US 2001-297963P | P 20010613 |
| | EP 1360169 | A2 | 20031112 | EP 2002-718949 | 20020211 |

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

| | | | | | |
|----------------|----|----------|-----------------|----|----------|
| | | | US 2001-268214P | P | 20010212 |
| | | | US 2001-297963P | P | 20010613 |
| | | | WO 2002-US4103 | W | 20020211 |
| HU 200303128 | A2 | 20031229 | HU 2003-3128 | | 20020211 |
| | | | US 2001-268214P | P | 20010212 |
| | | | US 2001-297963P | P | 20010613 |
| | | | WO 2002-US4103 | W | 20020211 |
| BR 2002007157 | A | 20040217 | BR 2002-7157 | | 20020211 |
| | | | US 2001-268214P | P | 20010212 |
| | | | US 2001-297963P | P | 20010613 |
| | | | WO 2002-US4103 | W | 20020211 |
| CN 1501909 | A | 20040602 | CN 2002-808112 | | 20020211 |
| | | | US 2001-268214P | P | 20010212 |
| | | | US 2001-297963P | P | 20010613 |
| JP 2004529877 | T | 20040930 | JP 2002-564477 | | 20020211 |
| | | | US 2001-268214P | P | 20010212 |
| | | | US 2001-297963P | P | 20010613 |
| | | | WO 2002-US4103 | W | 20020211 |
| NZ 539791 | A | 20061130 | NZ 2002-539791 | | 20020211 |
| | | | US 2001-268214P | P | 20010212 |
| | | | US 2001-297963P | P | 20010613 |
| IN 2003KN01015 | A | 20050708 | IN 2003-KN1015 | | 20030807 |
| | | | US 2001-268214P | P | 20010212 |
| | | | US 2001-297963P | P | 20010613 |
| | | | WO 2002-US4103 | W | 20020211 |
| NO 2003003538 | A | 20030811 | NO 2003-3538 | | 20030811 |
| | | | US 2001-268214P | P | 20010212 |
| | | | US 2001-297963P | P | 20010613 |
| | | | WO 2002-US4103 | W | 20020211 |
| US 2004044241 | A1 | 20040304 | US 2003-654756 | | 20030904 |
| | | | US 2001-268214P | P | 20010212 |
| | | | US 2001-297963P | P | 20010613 |
| | | | US 2002-73743 | A3 | 20020211 |
| ZA 2003007116 | A | 20041213 | ZA 2003-7116 | | 20030911 |
| | | | US 2001-268214P | P | 20010212 |
| US 2005096479 | A1 | 20050505 | US 2004-985292 | | 20041110 |
| US 7026508 | B2 | 20060411 | | | |
| | | | US 2001-268214P | P | 20010212 |
| | | | US 2001-297963P | P | 20010613 |
| | | | US 2002-73743 | A3 | 20020211 |
| | | | US 2003-654756 | B3 | 20030904 |
| US 2007037884 | A1 | 20070215 | US 2006-334223 | | 20060118 |
| | | | US 2001-268214P | P | 20010212 |
| | | | US 2001-297963P | P | 20010613 |
| | | | US 2002-73743 | A3 | 20020211 |
| | | | US 2003-654756 | B3 | 20030904 |
| | | | US 2004-985292 | A1 | 20041110 |

GI



AB A novel salt of O-desmethyl venlafaxine (I) is provided, I

succinate. Pharmaceutical compns., dosage forms and methods of use are also provided. Examples are given for the preparation of I, I monosuccinate and its monohydrate.

=> logoff hold

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

25.83

35.19

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-4.68

-4.68

SESSION WILL BE HELD FOR 120 MINUTES

STN INTERNATIONAL SESSION SUSPENDED AT 09:43:56 ON 29 JUN 2007